Absorption and distribution characteristics of 5-fluorouracil (5-FU) after an application to the liver surface in rats in order to reduce systemic side effects

被引:22
作者
Kodama, Yukinobu [1 ]
Fumoto, Shintaro [1 ]
Nishi, Junya [1 ]
Nakashima, Mikiro [1 ]
Sasaki, Hitoshi [2 ]
Nakamura, Junzo [1 ]
Nishida, Koyo [1 ]
机构
[1] Nagasaki Univ, Dept Clin Pharm, Grad Sch Biomed Sci, Nagasaki 8528521, Japan
[2] Nagasaki Univ, Sch Med, Dept Hosp Pharm, Nagasaki 8528501, Japan
关键词
chemotherapy; 5-fluorouracil; liver surface; pharmacokinetics;
D O I
10.1248/bpb.31.1049
中图分类号
R9 [药学];
学科分类号
1007 [药学];
摘要
The present study was undertaken to elucidate the absorption and distribution characteristics of 5-fluorouracil (5-FU) after its application to the liver surface in rats to examine the possibility of reducing the systemic side effects of this agent. 5-FU was applied to the surface of the liver by employing a cylindrical diffusion cell. Approximately 69% of the dose was absorbed in 360 min. The time course of the change in the amount of 5-FU remaining in the diffusion cell obeyed first-order kinetics. Also, a linear relationship was observed between the apparent permeability coefficient, P-app, and the reciprocal of the square root of the molecular weight of several compounds including 5-FU. The estimated P-app value of 5-FU was in good agreement with the experimental value. The plasma concentration of 5-FU was low (< 1.2 mu g/ml) until 360 min after the application. Following i.v. administration, 5-FU was rapidly eliminated from the plasma and could not be detected at 120 min. In the analysis of tissue distribution, the liver was divided into three sites; the region under the diffusion cell attachment site (site 1), the treated lobe excluding site 1 (site 2), and untreated lobes (site 3). After being administered i.v., 5-FU mainly distributed in the kidney, and the concentration in the liver was significantly lower than that in kidney, spleen, or heart. After its application to the liver surface, however, 5-FU preferentially distributed at site 1, and was not detected at the other sites or in other tissues. Thus, these results suggested the possibility of a reduction in the systemic side effect of 5-FU on its application to the liver surface.
引用
收藏
页码:1049 / 1052
页数:4
相关论文
共 26 条
[1]
Alexander H R Jr, 2000, Oncologist, V5, P416, DOI 10.1634/theoncologist.5-5-416
[2]
Hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma with portal vein tumor thrombosis - Analysis of 48 cases [J].
Ando, E ;
Tanaka, M ;
Yamashita, F ;
Kuromatsu, R ;
Yutani, S ;
Fukumori, K ;
Sumie, S ;
Yano, Y ;
Okuda, K ;
Sata, M .
CANCER, 2002, 95 (03) :588-595
[3]
Lattice intrahepatic doxorubicin with and without in-flow occlusion: a pharmacokinetic study of direct liver injection [J].
Averbach, A ;
Stuart, OA ;
Chang, D ;
Sugarbaker, PH .
EUROPEAN JOURNAL OF SURGICAL ONCOLOGY, 2000, 26 (01) :73-79
[4]
A phase II trial of continuous infusion of 5-fluorouracil, mitoxantrone, and cisplatin for metastatic hepatocellular carcinoma [J].
Ikeda, M ;
Okusaka, T ;
Ueno, H ;
Takezako, Y ;
Morizane, C .
CANCER, 2005, 103 (04) :756-762
[5]
KOIZUMI T, 1964, CHEM PHARM BULL, V12, P421
[6]
KOIZUMI T, 1964, CHEM PHARM BULL, V12, P413
[7]
Mok TSK, 2001, CANCER, V91, P2369, DOI 10.1002/1097-0142(20010615)91:12<2369::AID-CNCR1270>3.0.CO
[8]
2-3
[9]
Mossa M A, 1992, J Pharm Belg, V47, P129
[10]
Nakamoto T, 2000, ANTICANCER RES, V20, P4087